Wyeth heartburn drug is challenged

RSS

Wall Street Journal (subscription required), December 26, 2007

Wyeth faces an uphill struggle to protect patent exclusivity for its blockbuster drug Protonix after Teva Pharmaceutical Industries Ltd. launched a generic version of the heartburn pill in the U.S. market. Wyeth said it would file a patent-infringement claim against the Israeli generic-drug maker, seeking lost profits and other damages as a result of Teva's new product.

Full Story

Spine experts repudiate Medtronic studies

In an extraordinary move, a group of spine specialists are publicly repudiating the research of other experts that has backed the widespread use of a Medtronic bone growth product. In a series of reports...

Limits on test drugs add to patients' ordeals

Lorraine Heidke-McCartin, 54, has experienced heartening victories and wrenching setbacks in her fight with breast cancer. Last summer, her hopes were buoyed when her doctors said she was a good candidate to...

HHS trend scan will signal potential health IT breakthroughs

The Health and Human Services Department plans to develop and maintain a continuous scan of current and emerging health information technology innovations to help HHS agencies understand and be aware of...

go to complete list